Apollon Wealth Management LLC Has $1.23 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Apollon Wealth Management LLC decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 16.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,405 shares of the medical device company’s stock after selling 3,738 shares during the quarter. Apollon Wealth Management LLC’s holdings in DexCom were worth $1,234,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Taylor Frigon Capital Management LLC grew its position in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after buying an additional 11,075 shares in the last quarter. National Pension Service increased its holdings in DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Intact Investment Management Inc. acquired a new stake in DexCom in the third quarter valued at $650,000. Waters Parkerson & CO. LLC increased its holdings in DexCom by 4.2% in the second quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock valued at $30,912,000 after purchasing an additional 10,892 shares during the period. Finally, Legal & General Group Plc increased its holdings in DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on DXCM. Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Royal Bank of Canada decreased their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Leerink Partners decreased their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Finally, Stifel Nicolaus increased their price target on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $74.68 on Friday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The stock has a market cap of $29.17 billion, a price-to-earnings ratio of 44.72, a PEG ratio of 2.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm’s 50-day simple moving average is $69.77 and its 200 day simple moving average is $92.14.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.